Agilent’s Dr. Ganesh Bala explains how MAM-based LC–MS peptide mapping has become a foundational analytical tool for ADC and bioconjugate CQA monitoring in this Q&A piece.
Ganesh Bala
Advertisement
Ganesh Bala, PhD, is product specialist—mass spec at Agilent Technologies.
Articles by Ganesh Bala
Multi-attribute LC–MS methods improve characterization of complex bioconjugates, supporting scalable and regulatory-ready biotherapeutic development, says Agilent Technologies’ Dr. Ganesh Bala, who spoke at the 2026 AAPS National Biotechnology Conference.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Zai Lab’s Long-Acting Atopic Dermatitis Bispecific Points to Every-12-Week Dosin
2
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
3
What 3 Principles Guide Merck's Biologics and ADC Capacity Placement?
4
FDA Grants Kamau RMAT Designation to Nula-cel for Sickle Cell Disease
5